Sign in

CCEL on NYSE

CRYO CELL INTERNATIONAL INC

CRYO CELL INTERNATIONAL INC is an American misc health and allied services company, incorporated in Delaware.1 It is headquartered in Oldsmar, Florida.1 Its shares trade on NYSE under the symbol CCEL.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Marpai, Inc., PACIFIC HEALTH CARE ORGANIZATION INC or Charming Medical Ltd, or pick any stock.

  • TickerCCEL on NYSE1
  • IndustryServices-Misc Health & Allied Services, NEC1
  • HeadquartersOldsmar, Florida1
  • Incorporated inDE2
  • Business address700 Brooker Creek Blvd, Suite 1800, Oldsmar, Fl 346772
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Cryo-Cell International, Inc. (the “Company” or “Cryo-Cell”) is a Delaware corporation that was incorporated in 1989. The Company is organized in three reportable segments; 1.) cellular processing and cryogenic storage for family use, with a current focus on the collection and preservation of umbilical cord blood and tissue stem cells, 2.) the manufacture of PrepaCyte® CB Processing System (“PrepaCyte CB”) units, the processing technology used to process umbilical cord blood stem cells, and 3.) cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company, in combination with its global affiliates, currently stores over 250,000 cord blood and cord tissue specimens worldwide for the exclusive benefit of newborn babies and possibly other members of their families. Founded in 1989, the Company was the world’s first private cord blood bank to separa…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

1.5%Operating margin5
-7.7%Net margin5
-1.3%Revenue growth, 20255
$5.2MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Processing And Storage Fees brought in 99% of the revenue CRYO CELL INTERNATIONAL INC broke down this way in fiscal 2025.

  1. Processing And Storage Fees$31.4M599%down 1% from 2024
  2. Public Banking$129.5K50%down 65% from 2024
  3. Product$54.1K50%down 20% from 2024
Products and services by year
Products and services20242025
Processing And Storage Fees$31.6M$31.4M
Public Banking$366.7K$129.5K
Product$67.9K$54.1K

Business segments

Umbilical Cord Blood And Cord Tissue Stem Cell Service brought in 99% of the revenue CRYO CELL INTERNATIONAL INC broke down this way in fiscal 2025.

  1. Umbilical Cord Blood And Cord Tissue Stem Cell Service$31.4M599%down 1% from 2024
  2. Public Cord Blood Banking$129.5K50%down 65% from 2024
  3. Prepacytecb$54.1K50%down 20% from 2024
Business segments by year
Business segments20242025
Umbilical Cord Blood And Cord Tissue Stem Cell Service$31.6M$31.4M
Public Cord Blood Banking$366.7K$129.5K
Prepacytecb$67.9K$54.1K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue23¢$7.4M
  • Research and development1¢$376.3K
  • Selling, general and admin58¢$18.2M
  • Other costs11¢$3.4M
  • Interest7¢$2.1M
  • Income tax0¢$92.2K

Out of $31.6M in revenue.5 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending4¢$230.5K
  • Dividends paid59¢$3.2M
  • Share buybacks3¢$169.5K
  • Kept or used elsewhere34¢$1.8M

Out of $5.5M of cash from operations.5

Financial statements

Revenue6789105$31.6M in 2025−1% since 2019
0$10.0M$20.0M$30.0M$40.0M2019: $31.8M$31.8M20192020: $31.1M$31.1M2020−2%2021: $28.9M$28.9M2021−7%2022: $30.3M$30.3M2022+5%2023: $31.3M$31.3M2023+3%2024: $32.0M$32.0M2024+2%2025: $31.6M$31.6M2025−1%
Operating income6789105$482.4K in 2025−90% since 2019
-$15.0M-$10.0M-$5.0M0$5.0M$10.0M2019: $5.1M$5.1M20192020: $7.7M$7.7M2020+51%2021: $4.0M$4.0M2021−48%2022: $4.0M$4.0M2022+0%2023: -$12.3M-$12.3M20232024: $3.5M$3.5M20242025: $482.4K$482.4K2025−86%
Net income6789105-$2.4M in 2025
-$10.0M-$5.0M0$5.0M2019: $2.3M$2.3M20192020: $3.6M$3.6M2020+58%2021: $2.1M$2.1M2021−43%2022: $2.8M$2.8M2022+33%2023: -$9.5M-$9.5M20232024: $402.1K$402.1K20242025: -$2.4M-$2.4M2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-11-302024-11-30
Revenue$31.6M$32.0M
Cost of sales$7.4M$7.9M
Selling, general and administrative expenses$18.2M$18.5M
Impairment of public inventory$4.4M$0
Research, development and related engineering$376.3K$1.2M
Depreciation and amortization$751.5K$483.5K
Total costs and expenses$31.1M$28.5M
Operating Income$482.4K$3.5M
(Losses) gains on marketable securities-$806.3K$1.1M
Gain on interest rate swap$0$105.9K
Other income$53.0K$6.6K
Interest expense-$2.1M-$1.9M
Total other (expense) income-$2.8M-$676.2K
(Loss) income before income tax expense-$2.3M$2.8M
Income tax expense-$92.2K-$2.4M
Net (loss) income-$2.4M$402.1K
Net (loss) income per common share - basic-$0.30$0.05
Weighted average common shares outstanding - basic8.1M shares8.1M shares
Net (loss) income per common share - diluted-$0.30$0.05
Weighted average common shares outstanding - diluted8.1M shares8.2M shares

Compare CRYO CELL INTERNATIONAL INC with another company

Corporate structure

CRYO CELL INTERNATIONAL INC sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CRYO CELL INTERNATIONAL INC

  • Camac Partners, LLC Filed SCHEDULE 13D/A on CRYO CELL INTERNATIONAL INC, latest Jul 7, 2026 (2 filings since Mar 25, 2026)
  • CDMJ Nyberg Family Trust Filed SCHEDULE 13G on CRYO CELL INTERNATIONAL INC, latest Dec 27, 2024
  • ISZO CAPITAL LP Filed SC 13G/A on CRYO CELL INTERNATIONAL INC, latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • CRYO CELL INTERNATIONAL INC Oldsmar, Florida
    • Celle Corp. Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CRYO CELL INTERNATIONAL INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$27.6M5 Nov 30, 2025$27.5M5 Nov 30, 2024+0.2%
Accumulated depreciation$6.6M5 Nov 30, 2025$5.6M5 Nov 30, 2024+16.3%
Property and equipment, net$21.0M5 Nov 30, 2025$21.9M5 Nov 30, 2024−3.9%
Operating-lease assets (leased space)$819.6K5 Nov 30, 2025$806.3K5 Nov 30, 2024+1.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$319.0K5 Nov 30, 2025$561.0K5 Nov 30, 2024−43.1%
Marketable securities, current$3.0M5 Nov 30, 2025$2.9M5 Nov 30, 2024+1.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$1.9M5 Nov 30, 2025$1.9M5 Nov 30, 20240%
Intangible assets, net (excluding goodwill)$863.1K5 Nov 30, 2025$921.3K5 Nov 30, 2024−6.3%
Finite-lived intangibles, net$863.1K5 Nov 30, 2025$921.3K5 Nov 30, 2024−6.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$408.8K5 Nov 30, 2025$657.7K5 Nov 30, 2024−37.8%

Properties, in its own words

On July 18, 2022, the Company completed the purchase of a 56,000 square foot facility located near the Research Triangle Park in the Regional Commerce Center in Durham, North Carolina. The Company transferred $2,240,000 from cash on hand and financed the remaining balance of $8,960,000 with a term loan from Susser Bank (see Note 4).

The Company entered into a ten-year lease in April 2004 for its 17,600-square foot cGMP/cGTP compliant corporate headquarters in Oldsmar, Florida. The lease effectively commenced during October 2004, and the Company moved into this facility in November 2004. This facility contains the Company’s executive offices, its conference and training center, its laboratory processing and cryogenic storage facility and its scientific offices. In July 2018, the Company extended this lease through December 31, 2021. On January 11, 2021, the Company extended this lease through December 31, 2024. On May 2, 2023, the Company extended this lease through December 31, 2026. On July 8, 2025, the Company extended this lease through December 31, 2027.

The rest of Item 2

The Company entered into a one-year lease in July 2023 for an additional 800 square feet of office space in Miami, Florida for annual rent of approximately $48,000. The lease commenced during July 2023. On June 25, 2024, the Company entered into an extension of this lease for a two-year term for annual rent of approximately $53,000 commencing on July 1, 2024.

Rent charged to operations was $456,204 and $442,874 for the fiscal years ended November 30, 2025 and 2024, respectively, and is included in cost of sales and selling, general and administrative expenses in the consolidated statements of operations.

The future minimum rental payments under the current operating lease are as follows:

Fiscal Year Ending November 30, · Rent

2026 · 485,656

Item 2 of the 10-K filed Feb 27, 2026.4

Leadership

Who has led CRYO CELL INTERNATIONAL INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Mercedes Walton2006–2010
  2. David Portnoy2011–now
  3. Mark L. Portnoy2011–now

Chair

  1. David Portnoy2020–now

Chief financial officer

  1. Jill M. Taymans2006–now
2010201520202025
Board members and other officers (17)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Celle Corp. Delaware3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Sep 14, 20268-K Other events33
  2. May 8, 20268-K Listing notice or transfer; Regulation FD disclosure34
  3. Mar 12, 20268-K Listing notice or transfer; Regulation FD disclosure35
  4. Nov 12, 20258-K Other events36
  5. Oct 23, 20258-K Entered a material agreement; New debt or obligation37
  6. Sep 10, 20258-K Other events38
  7. May 22, 20258-K Ended a material agreement39
  8. May 8, 20258-K Other events40
  9. Oct 31, 20248-K Shareholder vote41
  10. Oct 30, 20248-K Other events42
  11. Oct 17, 20248-K Results of operations43
  12. Sep 17, 20248-K Other events44
  13. Sep 2, 2011New chief executive Mark L. Portnoy becomes CEO15
  14. Sep 2, 2011New chief executive David Portnoy becomes CEO14
  15. Apr 6, 2006New chief executive Mercedes Walton becomes CEO16

Calendar

When it reported results

  1. Oct 17, 2024Reported quarterly or annual results43
  2. Feb 24, 2022Reported quarterly or annual results45
  3. Oct 15, 2021Reported quarterly or annual results46

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

128 filings to the SEC since October 2021: 5 annual reports, 18 quarterly reports, 27 major events, 54 insider forms, 5 large holders, 19 other. The latest 20:

  1. Oct 13, 2026DEF 14A EDGAR
  2. Oct 13, 2026ARS EDGAR
  3. Oct 9, 202610-Q EDGAR
  4. Sep 14, 20268-K EDGAR
  5. Aug 7, 20264 EDGAR
  6. Jul 15, 202610-Q EDGAR
  7. Jul 7, 2026SCHEDULE 13D/A EDGAR
  8. May 29, 20264 EDGAR
  9. May 8, 20268-K EDGAR
  10. Apr 14, 202610-Q EDGAR
  11. Mar 25, 2026SCHEDULE 13D EDGAR
  12. Mar 12, 20268-K EDGAR
  13. Feb 27, 202610-K EDGAR
  14. Jan 9, 20264 EDGAR
  15. Jan 9, 20264 EDGAR
  16. Jan 9, 20264 EDGAR
  17. Jan 9, 20264 EDGAR
  18. Nov 24, 20254 EDGAR
  19. Nov 19, 20254 EDGAR
  20. Nov 12, 20254 EDGAR

The 128 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

25 open-market trades by officers, directors and large owners since October 2021: 20 buys and 5 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 18, 2025PORTNOY DAVIDChairman, Co-CEOBuy5,162$4.47$23.1KForm 4
Sep 17, 2025PORTNOY DAVIDChairman, Co-CEOBuy5,564$4.43$24.6KForm 4
Sep 16, 2025PORTNOY DAVIDChairman, Co-CEOBuy6,449$4.46$28.8KForm 4
Sep 10, 2025PORTNOY DAVIDChairman, Co-CEOBuy32,317$4.44$143.4KForm 4
Sep 9, 2025PORTNOY DAVIDChairman, Co-CEOBuy5,312$4.49$23.8KForm 4
Sep 8, 2025PORTNOY DAVIDChairman, Co-CEOBuy5,271$4.31$22.7KForm 4
Aug 27, 2025PORTNOY DAVIDChairman, Co-CEOBuy14,078$4.43$62.3KForm 4
Aug 26, 2025PORTNOY DAVIDChairman, Co-CEOBuy11,101$4.44$49.3KForm 4
Aug 25, 2025PORTNOY DAVIDChairman, Co-CEOBuy14,000$4.61$64.6KForm 4
Aug 19, 2025PORTNOY DAVIDChairman, Co-CEOBuy885$4.37$3.9KForm 4
Aug 18, 2025PORTNOY DAVIDChairman, Co-CEOBuy9,327$4.37$40.8KForm 4
Aug 15, 2025PORTNOY DAVIDChairman, Co-CEOBuy9,089$4.45$40.5KForm 4
Aug 14, 2025PORTNOY DAVIDChairman, Co-CEOBuy5,826$4.17$24.3KForm 4
Nov 18, 2022PORTNOY DAVIDChairman, Co-CEOBuy534$4.90$2.6KForm 4
Nov 17, 2022PORTNOY DAVIDChairman, Co-CEOBuy516$4.90$2.5KForm 4
Nov 15, 2022PORTNOY DAVIDChairman, Co-CEOBuy9,491$4.80$45.6KForm 4
Nov 15, 2022PORTNOY DAVIDChairman, Co-CEOSale16,000$4.80$76.9KForm 4
Nov 14, 2022PORTNOY DAVIDChairman, Co-CEOBuy10,000$4.80$48.0KForm 4
Nov 14, 2022PORTNOY DAVIDChairman, Co-CEOSale10,000$4.80$48.0KForm 4
Nov 11, 2022PORTNOY DAVIDChairman, Co-CEOBuy6,000$4.79$28.7KForm 4

All 25 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025David Portnoy$741.1K$1.6M50
2025Mark Portnoy$571.7K$1.1M50
2025Oleg Mikulinsky$329.9K$419.6K50
2025Jill Taymans$280.0K$326.7K50
2024Co-Chief Executive Officer$721.6K$1.6M50
2024Chief Information Officer$329.9K$425.2K50
2024Vice President FinanceChief Financial Officer$280.0K$332.3K50
2023Co-Chief Executive Officer$700.0K$1.6M50
2023Chief Information Officer$319.8K$405.1K50
2023Vice President FinanceChief Financial Officer$234.8K$301.9K50

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
SFI Advisors, LLC165,300$527.3K0.5%No change
Vanguard Capital Management LLC164,976$526.3K0.0%+3,452
MassMutual Private Wealth & Trust, FSB111,035$354.2K0.0%No change
Geode Capital Management, LLC46,273$147.7K0.0%+2,657
Vanguard Fiduciary Trust Co23,346$74.5K0.0%No change
Fmr LLC20,000$63.8K0.0%New
Susquehanna International Group, Llp14,064$44.9K0.0%+4,046
BlackRock, Inc.6,696$21.4K0.0%−7,287
Osaic Holdings, Inc.2,500$8.0K0.0%No change
Morgan Stanley605$1.9K0.0%+4
UBS Group AG316$1.0K0.0%−356
Barclays PLC14$450.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How CRYO CELL INTERNATIONAL INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCRYO CELL INTERNATIONAL INC1
  • CIK0000862692
  • Employer ID (EIN)22-30230934
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsNovember 301
  • Industry code (SIC)8090 Services-Misc Health & Allied Services, NEC1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address700 Brooker Creek Blvd, Suite 1800, Oldsmar, FL 346771
  • Phone813-749-21041
  • Shares outstanding8,062,650 as of Oct 8, 202613
  • Public float$26.5M as of May 31, 20254
  • AuditorWipfli LLP, Atlanta, Georgia PCAOB ID 344; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceFeb 28, 19971
  • Filings905 in all: 4 (332), 8-K (198), 10-Q (60), 10QSB (30), SC 13D/A (27), DEF 14A (26), DEFA14A (26), 10-K (19)1
    All 50 form types

    DFAN14A (19), 3 (17), S-8 (15), UPLOAD (15), 10KSB (11), CORRESP (9), SC 13G/A (9), NT 10-Q (7), DEFC14A (6), 10KSB/A (5), 4/A (5), NT 10-K (5), PREC14A (5), SC 13D (5), SC 13G (5), ARS (4), PRER14A (4), PRRN14A (4), 10-Q/A (3), PRE 14A (3), PREN14A (3), 10-K/A (2), 10QSB/A (2), 5 (2), 8-A12B (2), 8-K/A (2), CERT (2), DEFR14C (2), 25 (1), 3/A (1), 8-A12G (1), DEF 14C (1), DEFN14A (1), DEFR14A (1), RW (1), S-1 (1), S-1/A (1), SC TO-I (1), SC TO-I/A (1), SCHEDULE 13D (1), SCHEDULE 13D/A (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Feb 27, 2026
    Quarterly report (10-Q) Oct 9, 2026
    Proxy statement (DEF 14A) Oct 13, 2026
    Latest 8-K (8-K) Sep 14, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.01 par valueCCELNYSE American LLC

From the cover page of the 10-K filed Feb 27, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks CRYO CELL INTERNATIONAL INC names in Item 1A of its 10-K filed Feb 27, 2026: 41 risks under these headings, as written.4

  • Risk Related to our Business
  • Our common stock may be delisted from NYSE American LLC ("NYSE") if we fail to comply with continued listing standards.
  • We may need to raise additional capital.
  • We may not be able to successfully grow or operate our business.
  • The Company’s operations and performance depend significantly on global and regional economic conditions.
  • Because our industry is subject to rapid technological and therapeutic changes and new developments, our future success will depend on the continued viability of the use of stem cells.
  • If our umbilical cord blood stem cell storage services do not achieve continued market acceptance, we will not be able to generate revenue necessary to support our business.
  • We may fail to successfully manufacture MSCs.
  • Clinical development is lengthy and uncertain.
  • Our product candidates are subject to substantial government regulation, including the regulation of nonclinical testing and clinical trials. If we are unable to obtain regulatory approval for our product candidates, our ability to generate revenues related to such product candidate will be negatively impacted.
  • The stem cell preservation market is increasingly competitive.
  • A failure in the performance of our cryopreservation storage facility or systems, or those of Duke could harm our business and reputation.
The other 30 risks
  • Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.
  • There is uncertainty with regard to the outcome of the Duke Arbitration Demand.
  • There is uncertainty with regard to whether we will be able to maximize shareholder value through the Duke License Agreement.
  • We are not assured of recouping our damages related to the Arbitration Demand against Duke nor our investment in the Duke License Agreement.
  • From time to time, the Company is subject to proceedings, lawsuits, contract disputes and other claims in the normal course of its business.
  • Risk Related to Government Regulation
  • If we do not obtain and maintain necessary domestic regulatory registrations, approvals and comply with ongoing regulations, we may not be able to market our services in the United States.
  • We may be required to spend substantial amounts to comply with legislative and regulatory initiatives relating to patient privacy.
  • Our failure to comply with laws related to hazardous materials could materially harm us.
  • Risks Related to International Operations
  • Our international operations are subject to risk and we may not be able to successfully protect our intellectual property.
  • We are subject to the Foreign Corrupt Practices Act.
  • The Company’s business may be impacted by political events, international trade disputes, war, terrorism, natural disasters, public health issues, industrial accidents and other business interruptions.
  • Risks Related to Information Technology
  • Our information systems are critical to our business, and a failure of those systems could materially harm us.
  • If we experience a significant breach of data security or disruption in our information systems, our business could be adversely affected.
  • Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.
  • Some of our products contain open source software, which may pose particular risks to our proprietary software, technologies, products and services in a manner that could harm our business.
  • Risks Related to Intellectual Property
  • We may not be able to protect our intellectual property rights throughout the world.
  • We may become subject to third parties’ claims alleging infringement of their patents and proprietary rights, which could be costly, time consuming, and prevent the use of our technology solution.
  • If our security measures are breached, or if our services are subject to attacks that degrade or deny the ability of users to access our platforms, our platforms and applications may be perceived as not being secure, customers and suppliers may curtail or stop using our services, and we may incur significant legal and financial exposure.
  • Risks Related to being a Public Company
  • We incur significant costs and demands as a result of operating as a public company.
  • If we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately report our financial condition, results of operations or cash flows, which may adversely affect investor confidence in us and, as a result, the value of our common stock.
  • Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
  • Increasing scrutiny and changing expectations from investors, customers, and governments with respect to Environmental, Social and Governance (“ESG”) policies and practices may cause us to incur additional costs or expose us to additional risks.
  • Our principal stockholders and management own a significant percentage of our stock and will be able to exert
  • significant control over matters subject to stockholder approval.
  • We may become subject to securities class action litigation, which can be expensive, divert management attention, and, if resolved unfavorably, expose us to significant liabilities.
  • We are a “smaller reporting company” and, as a result of the reduced disclosure and governance requirements applicable to smaller reporting companies, our common stock may be less attractive to investors.
  • We are responsible for the indemnification of our officers and directors.
  • Certain provision of our charter, bylaws and Delaware law may delay, defer or prevent a tender offer or takeover attempt that public stockholders might consider in their best interest.
  • Certificate of Incorporation and Bylaws.
  • Delaware anti-takeover statute.

Legal proceedings

On January 6, 2023, a complaint styled Lindsey Lehr v. Cryo-Cell International, Inc., Case No. 50-2023-CA-000091, was filed in the Circuit Court for Palm Beach County, Florida, naming the Company as defendant and asserting claims on behalf of a putative class of individuals who entered agreements with the Company for umbilical cord blood storage services since May 2018. The complaint alleged that the Company’s advertising does not accurately represent the value and efficacy of its services and asserted claims (and sought unspecified damages) under Florida law. On March 14, 2023, the Company removed the case to the United States District Court for the Southern District of Florida (Case No. 9:23-cv-80405-AMC), and on March 21, 2023, moved to compel arbitration and stay the case. On October 10, 2023, the Court granted the Company’s motion to compel arbitration and stayed the case. On October 27, 2023, the plaintiff filed a demand for arbitration and statement of claims with the American Arbitration Association, and on January 18, 2024, the plaintiff filed an amended statement of claims dropping her class action

allegations against the Company. On March 19, 2024, the Company filed an answering statement and counterclaim in response to the plaintiff’s claims. On September 5, 2025, the plaintiff and the Company filed stipulations to dismissal of the American Arbitration Association proceeding, the United States District Court proceeding, and their respective claims with prejudice. The resolution of this matter did not have a material adverse effect on the Company’s business, consolidated financial position or results of operations. The Company does not include an estimate of legal fees and other related defense costs in its estimate of loss contingencies.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
    SEC EDGAROther events
  41. 41
  42. 42
    SEC EDGAROther events
  43. 43
  44. 44
    SEC EDGAROther events
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50